Loading data for ICU — first visit, this takes a few seconds.

알림

SeaStar Medical (ICU)

NasdaqCM: ICU · 실시간 가격 · USD

3.15

-0.03 (-0.94%)

종가 기준: Aug 26, 2026, 8:00 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.94% (1D)

데이터 없음

매수호가	2.31
시가총액	13.75M
매출 (ttm)	1.71M
순이익 (ttm)	-13.63M
	-1.04
	-1.89
	n/a
	-1.21
P/B (ttm)	3.10
P/S (ttm)	8.03
실적 발표일	n/a

매도호가	4.04
거래량	27,744
평균 거래량 (20일)	89,455
시가	3.23
전일 종가	3.18
일중 범위	3.15 - 3.24
52주 범위	2.07 - 12.50
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ICU 소개

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for ped...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 18, 2021

직원 수 18

상장 거래소 NasdaqCM

티커 ICU

웹사이트 https://seastarmedical.com

전체 기업 정보

재무 실적

2025년 SeaStar Medical의 매출은 1.23M로, 전년 135K 대비 814.07% 증가했습니다. 순이익은 -12.15M로, -51.07% 감소했습니다.

재무제표

어닝 서프라이즈

SeaStar Medical가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $495K 예상치 하회 $0, 및 68.94% 전년 대비 성장.
EPS -0.91 예상치 상회 0.06, 및 49.44% 전년 대비 성장.

뉴스

2주 전 · GuruFocus.com

SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...

Pediatric adoption doubles to 20 top children's hospitals, while Neutralize-AKI trial enrollment accelerates toward late-2027 PMA submission.

2주 전 · Motley Fool

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

Revenue surged 82% year-over-year as hospital adoption doubled to 20 sites.

3개월 전 · Moby

SeaStar Medical Holding Corporation Q2 2026 Earnings Call Summary

Moby summary of SeaStar Medical Holding Corporation's Q2 2026 earnings call

3개월 전 · GuruFocus.com

SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

SeaStar Medical Holding Corp (ICU) reports a 69% increase in Quelimmune net revenue and significant trial advancements, despite facing operational and market entry hurdles.

3개월 전 · Motley Fool

SeaStar Medical (ICU) Q1 2026 Earnings Transcript

Eric Schlorff: Thank you. With our growing presence and the continued adoption of Quellimmune in the pediatric AKI market, we believe we are on track to meet our net revenue goal of approximately $2 ...

2 페이지 중 1

SeaStar Medical (ICU)